Last month, Axplora participated in CPHI Worldwide, the unmissable annual event for global players in the pharmaceutical industry.
Let’s get back to this successful CPHI Barcelona 2023 edition in video with an exclusive interview from Dr. Sylke Hassel, led by Life Sciences Knowledge Hub, to discuss the key achievements, forces and breaking news of Axplora:
- Axplora’s broad and strong network of sites, with a global footprint both in Europe and India to answer all customers’ needs and serve patients worldwide.
- The appointment of Dr. Stephan Haitz as Novasep CDMO BU President, and Dr. Pere Paton as Chief Operations Officer, to reinforce Axplora’s position as a leader in the CDMO market.
- The introduction of the newly formed Scientific Advisory Board (SAB): five industry leaders in API development and manufacturing expertise such as Flow chemistry, Electrochemistry, Steroids, Biotechnology and Antibody Drug Conjugates (ADCs).
https://www.youtube.com/watch?v=mvg1cGAnPzw&t=187s
A year after the merger between Farmabios, Novasep and PharmaZell under the single brand Axplora, CPHI was the unique opportunity to look back over our first few months as a group. A wonderful anniversary for the brand and the teams working hard behind, with promising meetings and fruitful discussions. A great outlook for the future!
Latest news
Press Release
September 29, 2026
Axplora launching “Axotecan” to strengthen Global ADC supply
Independent European source of exatecan will expand choice and strengthen supply resilience for ADC developers Gram-scale material available, with validation batches targeted by the end of 2026 and GMP supply planned for late 2027 Cross-business collaboration combines Farmabios’ HPAPI expertise with Novasep CDMO’s integrated ADC capabilities September 29th, 2026 – Axplora, a global manufacturing […]
News
September 25, 2026
Axplora celebrates 60 years of innovation at Chasse-sur-Rhône
More than 300 employees, family members and guests joined the anniversary celebration on Saturday 19 September. Event honors six decades of expertise and the site’s continuing commitment to reliable, responsible manufacturing for customers and patients September 25, 2026 – Axplora, a global CDMO partner for complex small molecules and antibody-drug conjugates (ADCs), has marked 60 […]
News
August 05, 2026
Axplora’s sustainability strategy substantiated by SBTi as company accelerates action across its manufacturing network
Science Based Targets initiative (SBTi) validation provides independent confirmation of Axplora’s emissions-reduction targets. Targets reinforce Axplora’s commitment to helping customers build responsible, transparent and resilient pharmaceutical supply chains. Axplora’s ActNow 2030 initiative commits to reducing Scope 1 and 2 emissions by 42% and Scope 3 emissions by 25% by 2030. July 2026 – Axplora, a […]
We enable our partners to fully realize their ambitions.
Driven by the curiosity, skills and dedication of over 2,000 employees on three continents, Axplora delivers sustainable, technologically advanced API solutions to improve lives worldwide.